Trial Profile

Phase I trial in healthy volunteers of AG 014 bacteria for oral administration of certolizumab as a therapy for inflammatory bowel disease.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AG 014 (Primary)
Indications Inflammatory bowel diseases
Focus Adverse reactions; Pharmacokinetics
Sponsors ActoGeniX

Most Recent Events

29 Oct 2014 New trial record
15 Oct 2014 Results published in the Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com